Lb Pharmaceuticals (LBRX) Other Accumulated Expenses (2024 - 2026)

Lb Pharmaceuticals has reported Other Accumulated Expenses for 3 years, with the latest figure at $132000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses changed N/A year-over-year to $132000.0; the trailing twelve-month figure through Mar 2026 stood at $132000.0 (changed N/A YoY), and the FY2025 full-year result was $267000.0, up 17.11% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $132000.0, down from $267000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $267000.0 in Q4 2025, with the low at $132000.0 in Q1 2026.
• Average Other Accumulated Expenses over 3 years is $207000.0, with a median of $214500.0 recorded in 2024.
• Peak annual rise in Other Accumulated Expenses reached 17.11% in 2025, while the deepest fall reached 17.11% in 2025.
• Tracing LBRX's Other Accumulated Expenses over 3 years: stood at $228000.0 in 2024, then advanced by 17.11% to $267000.0 in 2025, then slumped by 50.56% to $132000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $132000.0 (Q1 2026), $267000.0 (Q4 2025), and $201000.0 (Q3 2025), per Business Quant data.

Peer Comparison